List of Medical Device Companies in France - 26

Affluent Medical est un nouvel acteur français de la medtech ayant pour ambition de devenir un des leaders européens dans les domaines cardiovasculaires et urologiques. Affluent Medical développe des implants innovants mini-invasifs de nouvelle génération pour restaurer des fonctions physiologiques essentielles dans ces domaines : - Kardiozis vise à prévenir les endofuites et les risques de récidive de l'anévrisme de l'aorte abdominale permettant aux patients de vivre plus sereinement face à un risque de rupture imprévisible ; - Kalios et Epygon visent à offrir des traitements chirurgicaux plus physiologiques pour la réparation ou le remplacement de la valve mitrale du cœur. Kalios permet de traiter les fuites résiduelles post-opératoire et l'insuffisance mitrale récurrente sans avoir à réopérer les patients. Epygon est aujourd'hui la seule valve transcathéter en développement permettant de restaurer les flux sanguins naturels et de sauvegarder le ventricule gauche. - Enfin, Artus est le premier sphincter artificiel activable électroniquement pour traiter l'incontinence urinaire d'effort des hommes et des femmes. Nos avancées technologies permettent d'offrir des dispositifs médicaux qui respectent davantage la physiologie du corps humain. Nos implants sont mis en place grâce à un chirurgie mini-invasive et visent à limiter les risques de récidive précoce ou tardif de la maladie. Les trois prothèses innovantes et la technologie d'Affluent Medical sont en phase sont préclinique ou clinique.

At Aton, we're building a team of expert companies dedicated to accelerating the progress of tomorrow's therapies. To help deliver the right treatment, to the right patient, at the right time. Aton's Ecosystem – Lifescience platforms united to transform therapies Our platforms are driving a fundamental shift in how medicines are developed. Toward products and services adapted to the patient's biology. Complimentary cutting-edge businesses, with unique technologies and diverse teams of experts. One goal. To accelerate discoveries for the good of patients, medicine, and society. Aton's platforms guide and support life-science businesses to achieve their goals with greater efficiency. Our Strategy We're driven by our ambition to develop tomorrow's therapies. We invest in, guide, support, and develop lifesciences companies with unique technologies. Our strategic investments focus on advancing personalized medicine. We collaborate with the brightest entrepreneurs, to provide flexible and longterm support. To ensure they reach their full potential — to help advance today's and tomorrow's medicines. To transform patient outcomes for good. Many specialists, working as one team, we're constantly moving forward, to take our place at the cutting-edge of medical advancements. We see the future of health. It's safer, targeted and more effective. We understand what it takes to deliver to health and regulatory requirements. Helping make this future a reality.

Bcv is a french Medtech company spin-off from the Intelligent Robotic Systems Laboratory (ISIR) at Sorbonne University and the Rothschild Foundation Hospital in Paris. A multidisciplinary team developing innovative technologies for endovascular procedures, for immediate improvement and future applications. Our first focus? STROKE Discover our actuable guidewire with electronically controllable shape-ability designed for the interventional neuroradiology procedures. Objective? Enhance endovascular access & navigation in any anatomy. Our first-ever Shape Memory Alloy actuated system is : - Suitable for minimally invasive interventions, - Unique, a single solution that could replace the package of traditional devices, - Ergonomic, its unique smart handle allows electronic actuation and a controllable torque of the catheter tip robotically to conform to arterial tortuosities, - Compatible and complementary with Robotics and Image Guided Therapy, in a patient-oriented specific design. Objective ? Reach the most complex parts of the human body, providing a game-changer solution for endovascular minimally-invasive procedures. Caution: Investigational device, not yet available for commercial sale, worldwide.

BIOCORP is a French company specializing in connected devices. Since October 2023, BIOCORP is a 100% Novo Nordisk company. The production plant is located in Issoire and the R&D and operational support teams in Cournon d’Auvergne. Every day, our 100 employees are mobilised around a single objective: to offer professional innovative solutions improving the daily life for patients. We develop innovative connected devices helping in the management of various diseases. As an example, we are offering Mallya, a medical device dedicated to patients living with diabetes, turning any insulin pen into a smart device. Our company is growing quickly but will not lose its start-up spirit! Do you have the taste for challenge and want to join a team focused on innovation, ready to reinvent itself every day? At Biocorp, we work with agility, for quality results and persistently in the aim of innovating. All of this in an environment that constantly seeks to promote well-being at work. Are you looking for a professional environment in which you can evolve, where your job is not a fixed definition of who you are, but the starting point of a career? Come and join us!

Clarteis is a French company located in Sophia Antipolis, known for its innovative dermatology medical devices. The company develops and manufactures CE-certified and FDA-approved products, emphasizing quality and innovation. Clarteis holds ISO 13485:2016 certification, ensuring high standards in its production processes. One of its key products is the exciplex®, a portable monochromatic excimer light device designed to treat various localized autoimmune skin conditions, including alopecia areata, vitiligo, psoriasis, atopic dermatitis, and mycosis fungoides. Clarteis has a global presence, with its products approved in over 45 countries, including the USA, Europe, and Japan. The company also offers support and resources for its products through a network of distributors and partners, promoting collaboration in the dermatological field.

CorWave is a French company developing innovative cardiac assist devices. CorWave's wave membrane pump is a breakthrough technology that differs from today's commercially available left ventricular assist devices (LVADs) by its physiological operation, designed to mimic a pulse and blood flow rates similar to those of a healthy heart. Ultimately, CorWave's membrane pump technology is expected to reduce the complications associated with current devices and improve the management of heart failure patients. A member of the French Tech 120, CorWave was founded in 2012 by start-up studio MD Start and is funded by renowned investors including Bpifrance, Exor Ventures, EIC Fund, Financière Arbevel, M&L Healthcare, Novo Holdings, Seventure Partners, Sofinnova Partners, Ysios Capital and Vlerick Group. The company has secured over €80 million in equity and employs over seventy people.

We want to provide people living with diabetes with an intelligent therapeutic system to regulate blood glucose. This project was initiated in 2011 by the CERITD (Centre d'Études et de Recherches pour l'Intensification du Traitement du Diabète) in collaboration with the CEA LETI. After the success of the clinical trials in 2014, we created Diabeloop to bring the project to market and make it available to the largest number of people. Since spring 2021, DBLG1 System, the first automated insulin delivery device, is being marketed in several European countries: Germany, Italy, Spain, Switzerland, the Netherlands and France.

FineHeartis a French medical device company focused on creatingtechnologies in the cardiovascular field. The FineHeartinvention, anI.C.O.M.S. (Implantable Cardiac Output Management System), is wirelessly powered, fully implantable mechanical circulatory support device that is able to optimize cardiac output while preserving the heart’s innate contractility.

At Guerbet, we build lasting relationships so that we enable people to live better. This is our Purpose. We place human cooperation at the heart of our relationships and actions. We are a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging. A pioneer since 95 years in the field of contrast media, we are a team of over 2,600 people globally, continuously innovating with 10% of revenue dedicated to Research & Development across four centers in France, Israel and the United States.

Hemerion is a clinical stage HealthTech company. Its first breakthrough technology jointly designed with University of Lille, Inserm and University Hospital of Lille, addresses brain cancer and aims to help patients in their fight against glioblastoma. Hemerion results of over 10 years of leading academic and clinical researches on innovative approaches to treat Glioblastoma. Today, Hemerion owns a unique and disruptive technology, already evaluated in frontline approach to treat patients harboring brain cancer.

Based near Bordeaux (FR), IMPLANET is an international company with a US subsidiary in Boston, funded by European institutional and private investors. IMPLANET focuses on spine and knee products. Its flagship product, the Jazz™ latest generation implant, is intended to improve the treatment of spinal disorders requiring spinal fusion surgery. Protected by 4 sets of international patents, Jazz™ has obtained 510(k) clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. Taking into account the evolution of the global healthcare system, the IMPLANET Marketing team identifies a portfolio of products and services based on a detailed analysis of socio-economic, regulatory, demographic and cultural specifications. The IMPLANET R&D team focuses on a scientifically and clinically proven implant design, using top quality materials tested to the highest prevailing standards, associated with simple and user-friendly instrumentation. Our various workgroups, composed of surgeons, experienced engineers and product managers work closely together to offer a range of implants with scientifically sound specifications and the highest quality to adequately respond to requirements of healthcare professionals. IMPLANET is able to provide the best of what science and experience have to offer, while ensuring to the stakeholders the best value for their products, their needs and demands.

Surgical equipment for different indications in ophthalmology and anterior segment conditions, innovative technology. Ultra-fast Femto Laser for #cataractsurgery, the only machine capable of performing a real #photoemulsification and removal of cataracted lens only with an Irrigation/aspiration cannula. Created in 2015 by @Fabrice Romano and 6 other co-founders, Keranova is the first company in the world able to bring to surgeons a new method for extracting the cataracted lens, by removing thousands of thin particles created with the ultra-fast laser. No more need for the phacoemulsification machine, just an irrigation/aspiration.

KOELIS has assisted urologists and radiologists from around the world in their routine clinical practice since 2006, providing the latest technology for personalized prostate cancer planning and management, from biopsy to active surveillance and treatment. Focused on developing advanced, targeted and less invasive solutions, KOELIS is committed to creating and bringing to the market a new paradigm in prostate cancer care, where physicians can offer the most personalized answers to their patients, avoiding any under or overtreatment and preserving quality of life. Thanks to cutting-edge imaging tools like Trinity® cartographer, which combines multiple imaging modalities with full 3D ultrasound, any suspicious lesion is characterized in a detailed 3D prostate map, offering a comprehensive and multiparametric approach and enhancing diagnostic confidence. The team at KOELIS innovates every day in collaboration with world-renowned universities and hospitals to offer physicians new advancements in imaging and a greater field of view, a must-have in active surveillance and targeted treatment. Based in Grenoble and Princeton, KOELIS technology has been featured in more than 50 clinical publications and treats more than 300,000 patients worldwide, including patients in Europe, United States, Canada, Japan, Australia, South America and the Middle East.

MSInsight, a French health-tech company, empowers the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status. MSI has been shown to be an indicator of treatment response, especially for immune checkpoint inhibitors, and as an important pan-cancer biomarker. We aim to propose bioinformatic tools for delivering insights on microsatellite mutational variations using Next-Generation Sequencing (NGS) data. Our flagship product, MSIcare, will be available as a robust diagnostic, prognostic, and theranostic assistant for guiding clinical decision-making.

NETRI is a technology enabling company that provides human cell based smart assays for high throughput preclinical data acquisition for the neurological Pharma & Cosmetics industries. We provide organs-on-chip solutions & interoperable in vitro models designed to deeply accelerate drug discovery and preclinical trials by mimicking in vivo neural connectivity.

Novian Health is a late-stage development medical device company based in Chicago, with a subsidiary, Novian Health SAS, in France. Novian Health has developed Novilase, a minimally invasive alternative to lumpectomy for the treatment of breast tumors using Interstitial Laser Therapy (ILT). Novian Health has received a CE Mark for focal destruction of malignant and benign breast tumors, the first thermal ablation device to be approved for breast cancer. Novian Health’s technology enables breast surgeons and radiologists to ablate tumors with image-guided laser therapy. Novilase offers significant advantages over surgery including fewer retreatments, quicker recovery, less pain and fatigue, minimal scarring, and only requires local anesthesia. Novian will conduct a multicenter pivotal trial to evaluate Novilase® laser therapy as a treatment for early-stage breast cancer. U.S. market clearance for the focal destruction of malignant tumors will be sought. Novian will begin commercialization in Europe. Novian Health has received U.S. FDA 510(k) clearance for the treatment of fibroadenomas, or benign breast tumors, and ablation of soft tissue. A registry has been initiated to collect additional information on benign breast tumors treated at centers around the U.S. www.novianhealth.com www.novilase.com

OPIA Technologies is a company dedicated to the development of medical devices with a specialization in ophthalmology but also provides services for medical devices compagnies. One of the main goals is to provide innovative and reliable devices to improve the diagnosis and care of patients with ocular diseases. OPIA is building a complete portfolio of medical devices for sampling ocular surface components (conjunctiva: EYEPRIM , tear film: TEARPRIM) and for non-invasive ocular drug delivery (IONTOFORVET), based on proprietary patents. Activities encompass the whole life cycles of the devices. The team of Opia design, manufacture and warrants the regulatory and quality conformity of its medical devices. Opia benefits from a privileged relationship with JB TECNICS (www.groupejbt.com), a worldwide group specialized in tool manufacturing and clean room molding for the medical industry. OPIA meets the highest level of quality requirements with a certified ISO 13485 quality management system (QMS). OPIA Technologies is also part of the company alliance JBT HUB UP (www.jbt-hubup.com) which offers a global solution for the development of complex medical devices, from inception to commercialization. The services provided by Opia Technologies for medical device companies concerns the following fields: - Project management - R&D - Proof of concept - Regulatory affairs - CE-marking and - Intellectual property/patents - Marketing strategy www.eyeprim.com www.iontoforvet.com

PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a prominent European Venture Capital firm specializing in Life sciences. PK MED was created around a small team of passionate and experienced experts in pharmaceutical and medical sciences, drug delivery and biomaterials design. PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Our expertise spans across critical healthcare domains, focusing on drug delivery systems for rheumatology and enhancing cell-homing techniques to improve bone marrow transplantation outcomes. The company has developed a portfolio of early projects in indications with high unmet medical needs, starting with Gout flare, Osteoarthritis and Hemoglobinopathies.

Founded in 1981 and based in Paris (France), Prothia has established itself in the world of medical devices and equipment and has acquired a particular understanding of cardiovascular, perinatal and rehabilitation applications. Our existing products and those in development create major global growth opportunities. We recently created our American structure in Massachusetts (Worcester). We look forward to meeting candidates interested in our field and our way of working. Prothia supports clinicians to help them achieve their therapeutic and diagnostic objectives. Listening attentively defines us. We strive to be helpful and do what we do well.

Quantum Surgical is a French company founded in Montpellier, France, speacialized in medical robotics and AI. Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide. Co-founded in 2017 and with a team of 110+ employees, Quantum Surgical is based in Montpellier, with offices in Miami, Florida. Quantum Surgical received the Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.

Established in 2015 and based in France, SafeHeal™ is a clinical stage medical device manufacturer. Specializing in the development of anastomosis protection devices for colorectal surgery, SafeHeal's premier device, Colovac, was invented by French surgeon Charam Khosrovani to eliminate the need for diverting ostomies in patients undergoing colectomy.

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Making Spine Surgery Safer SpineGuard is a French innovative medical company dedicated to the deployment and adoption of DSG® (Dynamic Surgical Guidance), powerful radiation-free real time sensing technology platform that spans a broad spectrum of skeletal applications from bone drilling instruments to automated placement of bone implants. Uniquely positioned to change the game in orthopedic robotic surgery. Devices, built with the DSG technology, give real-time audio and visual feedback to the surgeons to secure and streamline skeletal implant placement for the benefit of patients, surgeons, operating room staff and healthcare providers. The PediGuard probes are the only devices with built-in DSG capability to improve the accuracy of pedicle screw placement. The PediGuard probes are handheld tools used by spine surgeons to perform pilot holes in the vertebrae before pedicle screw placement. An electrical conductivity measurement sensor, located at the tip of the drilling instruments, alerts the surgeon in real time and without using X-Ray imaging, about changes in conductivity that occur at the transition between cancellous bone, cortical bone and soft tissues/ blood. These devices are used in surgeries for all kind of patients, from pediatric in deformity corrections to adult in degenerative diseases requiring internal fixation. These medical devices have assisted spine surgeons in accurately placing pedicle screws in over 90,000 spinal procedures around the world. With mounting clinical evidence (24 major Peer-Reviewed publications) confirming its efficacy, PediGuard devices are becoming a compelling answer to the clinical needs associated with safe and accurate pedicle screw placement.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

Urgo Medical is the wound-healing division of URGO group. Every day our 1600 employees are passionate about creating, developing and promoting highly innovative dressings and global solutions to heal people suffering from wounds. Our mission, as The Healing Company, is to make a significant difference for patients, healthcare professionals and the healthcare systems. In order to fulfil our mission: • Patient is at the heart of everything we do. • We keep innovating to develop the best in class solutions. • We have a pioneer and entrepreneurial mindset and we dare to take risks to find new solutions. This is why we are different. This is why we can make a difference. Our innovation and conqueror mindset enables us to be a dynamic Advanced Wound Care company.

About us Since its creation in 1962, continuous technological and market research, implementation of latest technology at all levels, dedication to customer satisfaction and high quality and reliability standards are the key factors in Vygon's growth. Vygon's name has become synonymous with quality and reliability in the field of single-use medical and surgical products. Know-how Our industrial culture grew along with the company. We now have 11 factories worldwide, and we manufacture some 210 million medical devices every year. 9 of our factories are located in Europe, including 5 in France. We inspect the entire production line, from procurement of raw materials through to distribution logistics. We guarantee the traceability of our products and quality control. Every pack we deliver results from the know-how and commitment of multidisciplinary teams that work together and learn from each other - the driving force behind Vygon. Conceived and designed by our engineers and technicians and manufactured in one of our 11 plants, Vygon products meet ISO 13485 standards as well as the environmental ISO standard 14001. 60 years after its creation, our group now has the support of 26 subsidiaries and 11 production sites, including 8 in Europe. Thanks to the hard work of its 2,619 employees, Vygon manufactures nearly 210 million medical devices every year.